Effect of an oral [alpha]2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus by Ortiz-Alonso, F. Javier et al.
Effect of an Oral a,-Adrenergic Blocker (MK-912) on Pancreatic Islet Function 
in Non-Insulin-Dependent Diabetes Mellitus 
F. Javier Ortiz-Alonso, William H. Herman, Barry J. Gertz, Vanessa C. Williams, Marla J. Smith, 
and Jeffrey B. Halter 
We used MK-912, a potent new selective 4-adrenergic receptor antagonist that is active orally, to study the effect of 
short-term, selective %-blockade on fasting plasma glucose (FPG) and pancreatic islet function in non-insulin-dependent 
diabetes (NIDDM). Ten asymptomatic patients with NIDDM received either a single oral dose of MK-912 (2 mg) or placebo in a 
double-blind, cross-over study. B-cell function was measured by the acute insulin response (AIR) to glucose (1.99 mmol/kg 
intravenously [Iv) and by the AIR to arginine (5 g IV) during a hyperglycemic glucose clamp at a mean glucose level of 32.1 
mmol/ L to provide an estimation of maximal B-cell secretory capacity. A-cell function was estimated by the acute glucagon 
response (AGR) to arginine during the glucose clamp. Effective %-adrenergic blockade was apparently achieved, as there were 
substantial increases of plasma norepinsphrine (NE) (P < .Ol) and both systolic blood pressure (SBP) (P < .Ol) and diastolic 
blood pressure (DBP) (P < .05) after treatment with MK-912, but not after placebo. MK-912 caused a significant (P < .05) 
although modest decrease of FPG that was associated with a small increase of fasting plasma insulin (P < O.Ol), C-peptide 
(P < .05), and glucagon (P < .Ol). FPG and hormone levels remained unchanged after placebo. MK-912 tended to increase the 
AIR (P = 95) and the C-peptide response (P = .07) to glucose compared with placebo. There was a small, but significant, overall 
treatment effect for both the AIR and AGR to arginine with MK-912 (both P < .05, ANOVA). These studies indicate that MK-912 
causes (1) sympathetic activation consistent with effective qadrenergic blockade; (2) a small decrease of FPG and a small 
increase of fasting plasma insulin; (3) a small improvement of B-cell function due to an increase in maximal B-cell secretory 
capacity; and (4) a small increase in basal and stimulated glucagon. These findings suggest that endogenous qadrenergic tone 
may contribute, although to a small extent, to the impaired B-cell function in NIDDM. If an q-blocker becomes available that 
does not increase BP, studies would be warranted to evaluate its potential impact on glucose regulation in patients with 
NIDDM. 
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S EVERAL ANIMAL and human studies have suggested a possible role for endogenous a-adrenergic tone in 
the impaired B-cell function in non-insulin-dependent 
diabetes (NIDDM).‘.” Adrenergic tone could negatively 
influence B-cell function by a postsynaptic q-adrenergic 
receptor mechanism that inhibits insulin secretion.‘-’ Al- 
though the improvement in B-cell function in NIDDM 
afforded by a-adrenergic blockade was small in previous 
studies,3,4 such an effect could be potentially useful in the 
clinical management of NIDDM. However, this would 
require the availability of a specific a,-adrenergic receptor 
antagonist that can be administered orally. 
MK-912 is a recently discovered potent and selective 
ch_-adrenergic receptor antagonist in both animals and 
humans.‘-“’ Clinical studies in healthy volunteers have 
demonstrated a general pharmacodynamic profile for MK- 
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912 consistent with ch_-adrenergic antagonist properties 
over a dose range of 0.1 to 2.0 mg orally, including a mild 
pressor response, an increase in circulating MHPG (3- 
methoxy-4-hydroxyphenylglycol) concentrations, and a mild 
axiogenic effect.’ More specific characterization of its I+- 
antagonist properties was achieved by blocking responses to 
an a,-agonist challenge with clonidine.“’ MK-912 inhibited 
clonidine-induced sedation, xerostomia, growth hormone 
release, hypotension, bradycardia, and hyperglycemia.‘” 
These findings support the use of MK-912 as a probe of the 
pathophysiologic involvement of az-mediated adrenergic 
tone in the impaired islet cell function of NIDDM. 
We used MK-912 to study the effect of short-term, 
selective m-blockade on plasma glucose levels and on 
pancreatic islet function in 10 patients with NIDDM in a 
double-blind, placebo-controlled, cross-over study. We also 
measured blood pressure and plasma catecholamine re- 
sponses to characterize the pharmacologic activity of MK- 
912 in this study population. 
METHODS 
Subjects 
Table 1 shows the clinical characteristics of the patients. Ten 
subjects (eight males, two females) with NIDDM were studied. 
Subjects were chosen with the following characteristics: (1) asymp- 
tomatic from hyperglycemia after medication was discontinued; (2) 
fasting plasma glucose (FPG) concentrations of 7 to 14 mmol/L 
( _ 125 to 250 mg/dL); (3) body weight not greater than 90 kg; and 
(4) less than lo-year history of diabetes. The presence of NIDDM 
was defined by National Diabetes Data Group (NDDG) criteria.” 
All patients were without evidence of retinopathy, nephropathy, 
neuropathy, or cardiovascular disease on physical examination, 
screening biochemical tests, and electrocardiogram (EKG). Pa- 
tients were treated with diet alone or a sulfonylurea that was 
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Table 1. Clinical Characteristics of the Patients 
Patient No. 
Age Duration of Diabetes Weight Ideal Body Weight GlUCOSd Insulin* 
w (Yr) (kg) (76.) (mmol/L) fpmol/L) 







1 36 2 84 118 11.2 93 0.5 146 
2 44 4 78 114 13.7 44 76 
3 46 3 80 113 13.6 75 0.7 159 
4 48 1 67 104 7.1 57 0.6 157 
5 48 1 74 109 9.4 78 0.8 159 
6 49 4 77 140 14.6 81 0.5 290 
7 50 3 89 123 11.1 66 0.3 74 
8 52 2 75 109 12.7 71 0.7 38 
9 58 3 85 138 11.7 116 85 
10 60 2 74 109 8.7 91 0.8 147 











tTo convert glucose values to mg/dL, multiply by 18. 
STo convert insulin values to plJ/mL, multiply by 0.171. 
§To convert C-peptide values to ng/mL, multiply by 3.02. 
YTo convert glucagon values to pg/mL, multiply by 1.0. 
/ITo convert norepinephrine (NE) values to pg/mL, multiply by 169. 
**TO convert epinephrine (EPI) values to pg/mL, multiply by 183. 
discontinued 3 weeks before the study, and on no medications that 
might interfere with catecholamine action. The study was approved 
by the Human Subjects Committee of The University of Michigan 
Medical Center. Informed consent was obtained from all subjects. 
Study Conditions 
Each patient received either a single oral dose (2.0 mg) of 
MK-912 or placebo in a double-blind, cross-over study. Study days 
were separated by 1 week. Patients were admitted to the Clinical 
Research Center of the University of Michigan Medical Center the 
night before each treatment day. They were fasting for 12 hours 
before treatment and refrained from taking any form of medication 
for a period of 2 weeks before and throughout the study period (3 
weeks in the case of sulfonylurea agents). Blood samples were 
obtained via a catheter inserted into a superficial wrist vein. To 
achieve arterialization of venous blood, the hand and wrist were 
warmed in a wooden box thermostatically heated to 60°C. A second 
intravenous (IV) line for infusions and injections was inserted in 
the contralateral antecubital vein. 
Protocol 
Figure 1 shows the mean plasma insulin and glucose levels for 
the 10 patients during the active drug day to illustrate the protocol. 
The IV lines were inserted 45 to 60 minutes before treatment. At 
10, 5, and 0 minutes before treatment, blood samples were 
obtained for baseline plasma glucose, insulin, C-peptide, and 
glucagon determinations. Plasma norepinephrine (NE) and epi- 
nephrine (EPI) were measured at 5 and 0 minutes before treat- 
ment. Patients then received orally a 2.0 mg dose of MK-912, or a 
placebo, with 1.50 mL of water. Thirty minutes after treatment, 
blood was obtained for glucose and hormone determinations. At 
50,55, and 60 minutes posttreatment, blood samples were obtained 
for plasma glucose and hormone measurement; plasma NE and 
EPI were measured at 55 and 60 minutes. At 60 minutes postdose, 
a bolus injection of glucose (1.66 mmol/kg) was administered over 
30 seconds as a 50% glucose solution. This was immediately 
followed by a variable infusion rate of a 20% glucose solution plus 
10 mmol/L KC1 via peristaltic pump in order to reach a steady- 
state plasma glucose level of approximately 30.0 mmol/L. Every 5 
minutes a blood sample was assayed for glucose determination by 
use of a Beckman portable glucose analyzer (Beckman Instru- 
ments, Fullerton, CA) and the glucose infusion adjusted accord- 
ingly. Blood samples were obtained at 3,4, 5, 7, 10, 15, 20, 25, 30, 
40,50,55, and 60 minutes after glucose bolus for determination of 
glucose, insulin, and C-peptide. Glucagon was measured at 50,55, 
and 60 minutes, and NE and EPI at 15, 30, 45, and 60 minutes 
following the glucose bolus. 
Sixty minutes later (120 minutes postdose and 60 minutes into 
the hyperglycemic clamp), a maximally stimulating dose of 10% 
arginine hydrochloride (5 g IV) was administered over 30 seconds. 
Blood samples were obtained at 2, 3, 4, 5, and 10 minutes after 
arginine administration for plasma glucose and hormone determi- 
nations. The glucose clamp was maintained for 10 minutes after the 
arginine challenge. One week after the first study, each patient 
returned for the second treatment period and followed the same 
protocol with the appropriate agent. 
Heart rate (HR) and blood pressure (BP) were monitored 
before and every 10 minutes after treatment for the first 3 hours, 
then at less frequent intervals until discharge from the study unit. A 
continuous single-channel EKG monitor was used to monitor the 
HR and rhythm. Screening biochemistry, hematology, urinalysis, 
and 12-lead electroencephalogram (ECG) were repeated after the 
final treatment for safety purposes. 
Calculations 
Several parameters were calculated. The mean change from 
baseline in plasma glucose, insulin, C-peptide, and glucagon 50 to 
60 minutes after treatment was calculated. The first-phase B-cell 
response to glucose was calculated as the mean of the insulin levels 
obtained 3 to 5 minutes after the IV glucose bolus minus the mean 
of the three prestimulus levels. The second-phase B-cell response 
to glucose was calculated as the area under the insulin curve 
(AUC) from 10 to 60 minutes during the hyperglycemic clamp. To 
estimate the maximal B-cell secretory capacity, the acute insulin 
response (AIR) to the B-cell stimulus arginine was calculated 
during the steady-state glucose level of 30 mmol/L (AIR-max).*2 
The AIR and the acute glucagon response (AGR) to arginine were 
calculated as the mean of the hormone levels obtained 2 to 5 
minutes after the arginine injection minus the mean of the three 
prestimulus hormone levels. The effect of MK-912 on plasma NE 
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Fig 1. Mean plasma insulin and glucose levels of 10 patients with 
NIDDM durlng the MK-912 protocol day. The drug (2 mg) was 
administered orally at 0 minutes. At 80 minutes, a bolus injection of 
glucose (1.88 mmoi/kg) was administered, followed by a variable 
giucosa infusion to reach and maintain a mean steady-state plasma 
glucosa concentration of approximately 90 mmol/L. A boius injection 
of argfnine (5 g IV) was administered after 80 mkmtes of glucose 
infusion, which was continued for 10 minutes following the arginine 
boius. On a separate day, the subjects underwent an identical 
protocol in whkh a placebo was administered instead of MK-912. 
Note that plasma insulin doubles, from 95 to 181 pmol/L (between 80 
and 120 minutes), when plasma glucose was increased from approxi- 
mately 10 to 30 mmoi/L. 
are reported as the average of the three lo-minute determinations 
over each 30-minute interval for the first 3 hours postdose. 
Analytical Methods 
Plasma glucose was measured by the Michigan Diabetes Re- 
search and Training Center (MDRTC) core laboratory with the 
hexokinase-glucose-6-phosphate dehydrogenase reaction (Gilford 
Impact 400E Automated System, Oberland, OH). Plasma immuno- 
reactive insulin (IRI) was assayed by the MDRTC laboratory using 
a double-antibody radioimmunoassay (RIA). Plasma immunoreac- 
tive glucagon (IRG) was assayed by the MDRTC with a double- 
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antibody RIA using ‘=I trace (New England Nuclear, Boston, 
MA).” Plasma catecholamines (NE and EPI) were measured by 
single-isotope enzymatic assay.14 
Statistical Analysis 
Each of the parameters was compared between treatments with 
the ANOVA model of Grizzle that contains factors for sequence, 
patient within sequence, treatment, and period.” There was no 
evidence of carryover. Data are expressed as mean ? SEM. 
Normality assumptions were tested with the Shapiro-Wilks statis- 
tic, and Hartley’s maximum F test was used to test the homogeneity 
of variance assumption. Results were considered significant at P < 
.OS (two-tailed test). 
RESULTS 
Treatment Periods 
As shown in Table 2, there were no differences in 
baseline plasma levels of glucose, insulin, C-peptide, gluca- 
gon, NE, and EPI between the two treatment periods. 
Similarly, the steady-state plasma glucose levels achieved 
during the hyperglycemic clamps were comparable during 
both drug and placebo days (31.4 f 0.6 v 32.8 k 0.9 mmol/L, 
P = NS). 
Effects of MK-912 on Plasma Catecholamines, BP, and HR 
Figure 2 shows plasma NE and EPI levels before and for 
2 hours after both treatments. MK-912 caused a significant 
increase over baseline in mean plasma NE (average change 
from baseline over 2 hours: A = +l.l t 0.3 nmol/L; 
P < .Ol) and EPI (A = +O.lO k 0.03 nmol/L; P < .Ol). 
There were no significant changes in mean plasma NE 
(A = +0.02 +- 0.07 nmol/L; P = NS), or EPI 
(A = +0.02 ? 0.03 nmol/L; P = NS), after the administra- 
tion of placebo. When these parameters were compared 
between treatments (MK-912 v placebo), a significant 
overall treatment effect was found for NE (P < .Ol) and 
EPI (P < .Ol). 
Figure 3 illustrates systolic (SBP) and diastolic (DBP) 
blood pressures, measured before and for 8 hours after 
both treatments. Both increased significantly over baseline 
after MK-912, but not after the administration of placebo 
(average change from baseline over g-hour observation 
period: ASBP = +lO f 2 v +3 +- 2 mm Hg, P < .Ol; and 
ADBP = +3 2 1 v -2 2 2 mm Hg, P < .05). No significant 
changes in HR over baseline were observed after the 
administration of MK-912 or placebo (data not shown). 
Table 2. Baseline* Fasting Levels of Plasma Glucose, and Hormones 
%fore the Admfnistratlon of Efther f#K-812 or placebo 
Drug Day Placebo Day 
Plasma glucose (nimol/L) 11.0 2 0.9 12.0 k 0.7 
Plasma insulin (pmol/L) 75 2 6 79 + 6 
Plasma giucagon (ng/L) 122 2 17 144*33 
Plasma C-peptide (nmol/L) 0.6 r 0.1 0.6 -c 0.1 
Plasma norepinephrine (nmoi/L) 1.0 k 0.1 1.0 t 0.1 
Plasma epinephrine (nmoi/L) 0.5 -t 0.1 0.5 2 0.1 
NOTE. All values are mean k SEM, N = 10. 
‘Baseline determined as the mean of the lo-, 5-, and O-, or 5 and 
O-minute, predose values, es appropriate. 
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Fig 2. Plasma norepinrphrlno (NE) and epinephrino (EPI) levels 
before and over a period of 2 hours after treatment. Both mean 
plasma NE and EPI increased over baseline during the 2 hours after 
the administration of MK-g12 (both P < .Ol), but not after placebo. All 
values are mean ‘_ SEM. n = 10. 
Effect of MK-912 on FPG and Hormone Levetk 
The changes from baseline for glucose, insulin, C-pep- 
tide, and glucagon were compared by ANOVA for the two 
treatment periods (MK-912 v placebo). A significant overall 
treatment effect was found for C-peptide and for glucagon 
(both P < .05), but the effects on glucose (P = .13) and 
insulin (P = .lO) did not reach statistical significance. 
Figure 4 illustrates the absolute changes from baseline 
for FPG and hormone levels 50 to 60 minutes after 
treatment and the within-treatment statistical evaluations. 
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Fig 3. Syatoiic (SBP) and diastolic (DBP) blood pressure before and 
over a period of 8 hours after treatment. Patients received either 
MK-gl2 or placebo at time 0. Both SBP (F < .Ol) and DBP Lp < .OB) 
Increased over baseline during the 8 hours after the admlnistration of 
MK-912, but not after pfacebo. All values are mean 2 SEW n = 10. 
FPG decreased slightly from baseline in nine of the 
10 subjects after the administration of MK-912 
(A = -0.43 f 0.13 mmol/L; P < .05), but remained 
unchanged after the administration of placebo 
(A = -0.13 +- 0.16 mmol/L; P = NS). Plasma insulin in- 
creased from baseline in nine of the 10 subjects after 
MK-912 (A = +23 2 6 pmol/L; P < .Ol), but remained 
unchanged after placebo (A = +4 k 6 pmol/L; P = NS). 
Plasma samples for C-peptide assay were lost from two 
patients. Plasma C-peptide increased from baseline in 
seven of eight patients after MK-912 (A = +0.12 + 0.03 
nmol/L, P < .05) and remained unchanged after placebo 
(A = -0.02 2 0.03 nmol/L; P = NS). Fasting plasma gluca- 
gon increased in eight of the 10 patients after treatment 
with MK-912 (A = +12 +- 4 rig/L,, P < .Ol), but remained 
unchanged after placebo (A = +2 + 9 rig/L;; P = NS). No 
significant correlation was found between FPG before the 
study or body weight and treatment effects on FPG or 
hormone levels. 
Effect of MK-912 on B-Cell and A-Cell Function 
Figure 5 shows the individual absolute differences be- 
tween treatments of the AIR and C-peptide (ACR) re- 
sponse to an IV glucose load. The AIR to glucose was 
greater with MK-912 than placebo in eight of the 10 
patients, an effect of borderline significance (43 +- 17 v 
21 + 10 pmol/L, P = .06). Similarly, the C-peptide re- 
sponse to glucose was greater with MK-912 than placebo in 
six of the eight patients in whom it was measured, but the 
difference did not reach statistical significance (0.07 + 0.03 
v 0.02 f 0.02 nmol/L, P = .07). 
The second-phase insulin response to glucose, measured 
as the area under the insulin curve from 10 to 60 minutes 
during the hyperglycemic clamp, was slightly greater with 
MK-912 compared with placebo, but this difference was not 
significant (2,274 2 656 v 1,889 k 433 pmol/L over 50 
minutes; P = NS). The area under the C-peptide curve 
from 10 to 60 minutes was also not different between 
MK-912 and placebo (16 f 4 vs 19 2 5 nmol/L over 50 
minutes; P = NS) in the eight patients in whom it was 
measured. 
During the hyperglycemic clamp (from 60 to 120 min- 
utes), the increase in average plasma glucose from approxi- 
mately 10 to 30 mmol/L caused an increase of plasma 
insulin with MK-912 (from 95 + 8 to 181 +- 23 pmol/L) and 
placebo (from 83 + 12 to 155 f 18 pmol/L). The differ- 
ences between MK-912 and placebo were not significant. 
Figure 6 illustrates the individual absolute differences 
between treatments of the AIR, C-peptide (ACR), and 
glucagon (AGR) response to IV arginine during the hyper- 
glycemic clamp. The AIR to arginine at this FPG level is 
maximal and estimates B-cell secretory capacity. The AIR 
was greater with MK-912 than placebo in eight of the 10 
patients and there was a significant overall treatment effect 
(702 + 96 v 604 f 91; P = .02). In contrast, ACR to argi- 
nine was slightly greater with placebo than with MK-912, 
but the difference was not statistically significant (1.3 + 0.1 
v 1.4 2 0.2 nmol/L, P = NS). The AGR to arginine was 
greater with MK-912 than placebo in eight patients, and 
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there was a significant overall treatment effect (116 2 21 v 
83 ? 21 rig/L;; P < .05). 
No significant correlation was found between FPG be- 
fore the study or body weight and any of the parameters 
used to measure B- and A-cell function. 
Adverse Effects 
There were no clinically meaningful changes in hematol- 
ogy, blood chemistry, urinalysis, or EKG considered to be 
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Fig 4. Absolute change from base- 
line, for each study subject, of fastbrg 
plasma glucose (PG), insulin (IRI), 
C-peptfde (C-Peptj, and ghtcagon (RIG) 
at 50 to 60 minutes after treatment. 
FPG decreased and hormone levels 
increased sfgnfffcantiy aftar the admin- 
istration of MK-912, but not after pla- 
cebo (P values reflect wfthin-treat- 
ment comparisons). 
vasovagal episode after dosing with MK-912 and shortly 
after micturition, which rapidly resolved without sequela. 
MK-912 appeared to be well tolerated by all subjects. 
DISCUSSION 
In the present study, we used a new orally active and 
selective %-blocker, MK-912, to determine whether in- 
creased g-adrenergic tone may be contributing to impaired 
B-cell function in NIDDM, and to evaluate the potential 
role of reducing g-adrenergic tone in the management of 
0 
0 
+ P - 0.07 
0 . . .._.._-._---.__.....-.-. 
w 
. . . . . . . ..__.__._.._.__________ 
0 
Fig 5. Absolute difference between MK-912 and placebo of each study subject for the acute insulin response (AIR) and acute C-peptlde 
response (ACR) to glucose (1.66 mmol/ kg IV). The AIR to glucose was greater with MK-912 than placabo in eight of the 10 subjects and the ACR to 
glucose in six of the eight subjects in whom it vves measured, but the mean dlffemnces were of borderftne signKkanw fP < .07). 
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Fig 6. Absolute difference between 
MK-912 and placebo of each study 
subject for the acute insulin response 
(AIR), acute C-peptide response (ACM 
and acute glucagon response (AGR) to 
arginine (5 g IV) during the hyperglyce- 
mic clamp. The AIR and AGR to argi- 
nine were greater in eight of the 10 
subjects with MK-912 than placebo, 
but there was no treatment effect on 
the ACR to arginine. 
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NIDDM. Animal studies have shown that MK-912 reduced 
the FPG concentration and improved glucose tolerance in 
the insulin-resistant, hyperglycemic, ob/ob mouse mode1.16 
The effectiveness of cr,-blockade following MK-912 is 
indicated by the consistent increase of plasma catechol- 
amines and BP as observed with other a,-antagonists in 
man.17.18 The observations of the effects of MK-912 on 
plasma catecholamines in patients with NIDDM extend 
those made in normal volunteers’ in which a mild pressor 
effect and an increase in plasma MHPG, an index of overall 
adrenergic function,” were demonstrated. These effects of 
MK-912 suggest central ar,-receptor antagonism.” 
In the present study, we found a small increase in 
baseline plasma insulin with MK-912 that was associated 
with a small decrease in FPG. These results are consistent 
with recent studies with MK-912 in normal volunteers, as 
well as studies in which Midaglizole (Daiichi Pharmaceuti- 
cal, Tokyo, Japan), a novel low-affinity q-adrenergic blocker, 
caused an increase in fasting plasma insulin and a modest 
decrease in FPG in normal subjects, and improved postpran- 
dial hyperglycemia in NIDDM.20,21 However, in the latter 
studies, the specificity of Midaglizole as an cw,-adrenergic 
blocker was not demonstrated. Although the effectiveness 
of 2.0 mg MK-912 as an ol,-blocker has been demonstrated 
in previous studies using the cu,-agonist clonidine as a 
challenge,” we cannot rule out some other mechanism of 
action on glucose regulation. 
Our finding of a slight improvement in AIR-max with 
MK-912 may suggest a small restoration of the maximal 
B-cell secretory capacity with q-blockade in NIDDM. This 
is consistent with previous studies that showed a modest 
improvement of B-cell function in NIDDM with the nonspe- 
cific u-blocker phentolamine.3,4 However, we cannot rule 
out the possibility that MK-912 may enhance B-cell func- 
tion by a nonadrenergic mechanism, as suggested recently 
for phentolamine.7 An additional mechanism to explain 
improved B-cell function with g-blockade would be an 
increase in synaptic NE release and a subsequent increased 
p-adrenergic effect on B cells leading to increased insulin 
secretion, as Broadstone et al have recently suggestedP 
Compared with the significant treatment effect on the 
insulin response to arginine, the C-peptide response was 
not different between MK-912 and placebo. This apparent 
contradiction may be explained by differences in the kinet- 
its of C-peptide compared with insulin. Changes of C-pep- 
tide levels do not reflect acute changes of insulin secretion, 
as well as plasma insulin levels.” The apparent contradic- 
tion might also be explained by an augmented secretion of 
proinsulin in response to MK-912, as proinsulin is not 
differentiated from true insulin by the immunoassay.Z3 
The marginal effects of MK-912 on the first- and second- 
phase insulin responses to glucose are consistent with its 
modest effect on B-cell secretory capacity, and is also 
consistent with a recent study that failed to find any 
improvement in the first- and second-phase insulin re- 
sponses to glucose with the specific q-blocker ldazoxan 
(Rack& & Colman, Kingston upon Hull, UK) in a small 
number of patients with NIDDM.” An alternative explana- 
tion could be that the degree of hyperglycemia (>30 
mmol/L) at which the second-phase insulin response was 
1166 
measured may have overwhelmed an qblocking effect that 
might have been more evident at lower plasma glucose 
levels. 
The mild, but significant, enhanced A-cell function with 
MK-912 is particularly noteworthy in the presence of 
increased insulin levels, which would tend to suppress 
glucagon secretion.” This may suggest that the effect of the 
drug on A-cell function is not entirely the result of a 
primary effect on B-cell functionF6 These results are also in 
apparent discrepancy with the results observed with Mida- 
glizole,” although that study was conducted in normal 
subjects. The improvement in A-cell function with q- 
blockade may be explained by an increase in synaptic cleft 
NE secondary to presynaptic q-blockade, resulting in an 
accentuated B-adrenergic stimulation of A cells. 
Other points merit discussion. First, it is possible that the 
degree of a patient’s prior hyperglycemia or adiposity might 
influence endogenous ol,-adrenergic tone, and thereby the 
degree of effects of MK-912. We found no relationship 
between glucose control before the study or body weight 
and the positive effects of the cY,-adrenergic blocker MK- 
912 on FPG or B-cell function. However, due to the small 
sample size, the broad range of FPG (7 to 14 mmol/L), and 
the fact that our patients were “relatively” non-obese as 
compared with much of the NIDDM population, these 
findings must be interpreted with caution. Second, the 
significance of the small improvement in B-cell function 
with MK-912 cannot be fully assessed without a comparable 
study on age- and weight-matched normal subjects, which 
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was not done in the present study. Third, the increase of 
catecholamines and BP is of concern in patients with 
NIDDM. Any potentially useful therapeutic effect of an 
qadrenergic blocker such as MK-912 on B-cell function of 
patients with NIDDM must be carefully weighed against 
these secondary changes. 
In summary, in the present study, we have shown that in 
patients with NIDDM a single 2.0-mg oral dose of MK-912 
causes (1) an effective q-blockade with increases in plasma 
catecholamines and BP; (2) a small increase of fasting 
plasma insulin levels, associated with a small decrease of 
FPG level; (3) a small improvement in B-cell function due 
to an increase in maximal B-cell secretory capacity; and (4) 
a small increase in basal and stimulated plasma glucagon 
concentrations. These findings suggest that endogenous 
qadrenergic tone may contribute, although to a small 
extent, to the impaired B-cell function in NIDDM. If an 
qblocker becomes available that does not increase BP, 
studies would be warranted to evaluate its potential impact 
on glucose regulation in patients with NIDDM. 
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